Avant Immunotherapeutics (MM) (AVAN)

Avant Immunotherapeutics Inc - Current report filing (8-K)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT...

Avant Immunotherapeutics Inc - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Avant Immunotherapeutics Inc - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Avant Immunotherapeutics Inc - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Avant Immunotherapeutics Inc - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Avant Immunotherapeutics Inc - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

AVANT Immunotherapeutics Announces Name Change to Celldex Therapeutics

AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) (the ?Company?), today announced that, pursuant to a previously announced...

Avant Immunotherapeutics Inc - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Avant Immunotherapeutics Inc - Confidential Treatment Order (CT ORDER)

AVANT CEO To Present at the UBS 2008 Global Life Sciences Conference September 23

AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, Interim President and Chief Executive...

Avant Immunotherapeutics Inc - Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Company x...

AVANT CEO to Present at the 28th Annual Canaccord Adams Global Growth Conference

AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, interim President and Chief Executive...

Avant Immunotherapeutics Inc - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES...

CORRECTING and REPLACING AVANT Reports Second Quarter and Six Month Financial Results

Please replace the release with the following corrected version due to multiple revisions. AVANT REPORTS SECOND QUARTER AND...